Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Dumbrava, E., Sharma, M. R., Carvajal, R. D., Catenacci, D., Emens, L. A., Gadgeel, S. M., Hanna, G. J., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B. T., Moore, K., Pegram, M. D., Pohlmann, P. R., Rasco, D., Spira, A., Tan, A. R., Ackerman, S. E., LeBlanc, H., Dornan, D., Kowanetz, M., Alonso, M. N., Perez, E. A. AMER ASSOC CANCER RESEARCH. 2021
View details for Web of Science ID 000618737700036